hplc-analytical-chem-2018-scientifictracks

6 / 20

Page 37
Notes:
Journal of Analytical & Bioanalytical Techniques | ISSN: 2155-9872 | Volume 9
World HPLC, Separation Techniques & Pharmacovigilance
World Analytical Chemistry & Mass Spectrometry
18th International Conference on
August 29-30, 2018 | Toronto, Canada
&
Effects of policosanol in the functional recovery of ischemic stroke hypertensive patients
Julio C Fernandez1 Javier Sanchez 2, Jose Illnait, Lilia Fernandez, Sarahi Mendoza, Rosa Mas, Pablo Reyes and Meilis Mesa3
1National Centre for Scientific Research, Cuba
2Institute of Neurology and Neurosurgery, Cuba
3Surgical Medical Research Centre, Cuba
Introduction: Stroke is one of the leading causes of mortality and disability. Clinical studies results show that policosanol (20
mg/day) + standard aspirin (AS) therapy had benefits versus placebo + AS given for 6 and 12 months to patients with recent
ischemic stroke.
Objective: To analysis, the policosanol treatment effects in the hypertensive patients included in two ischemic stroke recovery
trials.
Methods: This report was analyzed the records of all hypertensive patients included in two ischemic stroke recovery studies.
Hypertensive patientswith amodifiedRankin Scale score (mRSs) 2 to 4were randomized, within 30 days of onset, to policosanol/
AS or placebo/AS, for 6 months. The primary outcome was a mRSs reduction. Low-density Lipoprotein-cholesterol (LDL-C)
reduction and High-Density Lipoprotein-Cholesterol (HDL-C) increase were secondary outcomes.
Results: One hundred forty-two hypertensive patients (mean age: 66 years) were included in the analysis. Policosanol/AS
decreased significantly the mRSs mean from the first interim check-up (3 months) (p<0.0001 vs. placebo/AS). The policosanol
treatment effect did not wear off, on the contrary, even improved after 6 months therapy (p<0.0001 versus placebo/AS).
Moreover, policosanol/AS (57/71; 80.3%) treatment achieved significant results (mRSs ≤1; p<0.0001). Whereas the placebo/
AS did not (6/71; 8.5%). Treatments were well tolerated. Two patients discontinued prematurely and four patients (2 from
policosanol/AS group and 2 from placebo/AS) referred mild AE.
Conclusions: Six months administration of policosanol/AS given to hypertensive patients after suffering ischemic stroke
demonstrated to be better than placebo/AS in improving functional outcomes at 3 and 6months when used among hypertensive
patients with ischemic stroke.
Biography
Julio Cesar Fernandez Travieso is a Senior Investigator in the Clinical Trials Unit, National Centre for Scientific Research, Havana, Cuba. He has completed his BSc
in Pharmaceutical Sciences from Havana University, Cuba in 1996. He was awarded PhD in Pharmaceutical Sciences in 2003. He has published more than 130
publications and presented more than 100 papers in various scientific events. His research interest mainly focuses on clinical trials phase I-IV of different natural
products: Policosanol, Abexol, Prevenox and Palmex.
Julio C Fernandez et al., J Anal Bioanal Tech 2018, Volume 9
DOI: 10.4172/2155-9872-C1-027